SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
about
Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinomaChinese guidelines on the management of renal cell carcinoma (2015 edition)Sunitinib in the treatment of metastatic renal cell carcinomaExpert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations.Sunitinib as salvage treatment including potent anti-tumor activity in carcinomatous ulcers for patients with multidrug-resistant metastatic breast cancerCorrelation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implicationsEffects of stimulating interleukin -2/anti- interleukin -2 antibody complexes on renal cell carcinoma.Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study.Pazopanib as a second-line treatment for non-cytokine-treated metastatic renal cell carcinoma: a meta-analysis of the effect of treatment.A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapyEfficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis.Tyrosine kinase inhibitors improve parenchymal findings of liver cirrhosis in a patient exhibiting concomitant hepatocellular carcinoma and renal cell cancer.Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer.Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study.Nivolumab in renal cell carcinoma: latest evidence and clinical potential.Targeted therapy for renal cell carcinoma: focus on 2nd and 3rd line.Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer.Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma.Sunitinib in kidney cancer: 10 years of experience and development.Pharmacotherapy for treating metastatic clear cell renal cell carcinoma.The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges.Survival outcomes of double- and triple-sequential targeted therapy in patients with metastatic renal cell carcinoma: a retrospective comparison.Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry.Network meta-analysis of second-line treatment in metastatic renal cell carcinoma: efficacy and safety.Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017.Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence.Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis.[Genitourinary malignancies and rheumatoid arthritis].Predictive Factors for Second-Line Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Analysis.Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors.Systemic therapy in metastatic renal cell carcinomaSurgical Complications of Presurgical Systemic Therapy for Renal Cell Carcinoma: A Systematic ReviewSunitinib rechallenge with dose escalation in progressive metastatic renal cell carcinoma: A case report and literature review
P2860
Q26766240-940390F0-3C9C-47B2-8DD6-857EF31122A9Q26772206-DB76C8E4-DB97-499D-993F-E070B82C61FAQ28072057-335762C1-BD2D-4D71-B816-A877A2CCCCF3Q30382892-8FB4645A-A513-4F61-B6E6-E1485A646BAEQ33434465-12B2BEAF-6ECF-49BE-A865-8F2EC322E2DAQ33779585-C5F0CB72-CF8F-45F5-83F8-3B949AB3BC02Q35895478-F9B4BEF1-10D4-4138-BE7A-F74F5BB2B227Q35932363-92464427-135B-4A60-B638-1FEEE2ED05E6Q36067852-18B7DFEE-1EEE-4BE8-8A2E-95B1AFBAF7D4Q36092829-4BF6DE24-A370-46DB-8651-9C8ADA6F84C4Q36252946-B2A4A15A-FF32-42D3-9830-48373A599F34Q36524508-7BC44F34-DDFA-4145-B48D-31B5ADF7ECF3Q37151272-53AE40C2-BB6B-4D18-A0DA-D3F033B183ECQ37290050-5118C737-1C4E-46F5-89F1-304644C0F950Q37698611-F0B324D1-2BF9-427E-9C6C-307A89B4D7BCQ38656760-8E7A9087-CA4D-41E3-894C-BA66ED059820Q38757723-30F27EDB-4932-40DB-9FD8-D98E63ACCD5BQ38799848-3847ED0E-A52A-4EE2-A236-8C155BA5881DQ38860807-6F0C040C-71E0-49F2-8C87-7AA27095AF0DQ38868038-0F2519CB-C265-4B63-BC0D-C46721AFD471Q39038214-4C8E2458-BEE0-41E7-9809-B7404E527500Q39095194-86F025F7-AF7C-4180-8E87-5EF9F6298FA6Q39096266-11BEB302-C6F0-45AC-B067-3DA3F9144BE0Q47134616-5549B11F-132F-40D5-8940-2E23E46DDFFCQ47265255-E763FC6C-2A4C-4D4C-8EF1-D262AF343A79Q47813600-FD703B8D-F73B-4AC7-8EBB-ACB2CE975564Q49573718-AAE023CC-8015-498C-B962-B13B5B8CCC06Q52319542-CC25E3CB-13C3-4FBD-8198-E889D89DECA1Q52680262-10CAE070-1DD9-4125-A97C-EA7EB7263EFDQ52857466-80FCCF55-54A0-47F1-B36F-6742478F221CQ53634559-EC51157E-0C0C-4BCF-A032-B35C06D49B69Q54119475-A178D49D-B06B-4D4C-B758-4C57761CFF80Q56966129-7EB04090-5DC8-40DD-A0EB-6AF970948ECFQ58585062-A23B3778-E010-454F-8632-3EF9A28F83B2Q58802067-20FA2344-82D8-433A-A5BA-F5E6FF3D8484
P2860
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
SWITCH: A Randomised, Sequenti ...... Metastatic Renal Cell Cancer.
@en
type
label
SWITCH: A Randomised, Sequenti ...... Metastatic Renal Cell Cancer.
@en
prefLabel
SWITCH: A Randomised, Sequenti ...... Metastatic Renal Cell Cancer.
@en
P2093
P1433
P1476
SWITCH: A Randomised, Sequenti ...... Metastatic Renal Cell Cancer.
@en
P2093
Anne Flörcken
Christian Eichelberg
Christian Lerchenmüller
Cornelis van Arkel
Dana Gottstein
Kirsten Hauswald
Ludwig Fischer von Weikersthal
Maartje Los
Marcus Schenck
Maria De Santis
P304
P356
10.1016/J.EURURO.2015.04.017
P407
P577
2015-05-04T00:00:00Z